Dr. Martin P. Levinson, M.D.
Pediatrics (Pediatrics Physician)
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatrics Physician primary
MI license 4301042276
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 36 payments worth $761 in total to this clinician.
| Collegium Pharmaceutical, Inc. | $215 |
|---|---|
| Corium, LLC | $156 |
| Alk-abello, Inc | $94.34 |
| GlaxoSmithKline, LLC. | $54.48 |
| Cranial Technologies, Inc | $53.32 |
| Sanofi-aventis U.S. LLC | $48.08 |
| Pfizer Inc. | $33.89 |
| Tris Pharma Inc | $32.50 |
| Food and Beverage | $761 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 3 companies. The companies reported $86,903 in research payments for these studies, mostly to the institutions running them.
- A phase 3A, observer-blind, randomized, controlled study to demonstrat
GlaxoSmithKline, LLC. - A phase 3 randomized placebocontrolled observerblinded trial to evaluate the safety of a 6VALENT ospabased lyme disease vaccine VLA15 in healthy children 5 through 17 years of age
Pfizer Inc. - A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation
AbbVie Inc. · Completed · NCT05652205 - M21-572 - A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation
AbbVie Inc. - A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide
AbbVie Inc. · Completed · NCT05760313 - A phase ii, single-blind, randomized, controlled study to evaluate the
GlaxoSmithKline, LLC. - A phase 3 protocol to investigate the safety tolerability and immunogenicity of a BNT162B2 LP81ADAPTED vaccine in children 5 through 11 years of age considered at high risk for severe COVID19
Pfizer Inc. - A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines
AbbVie Inc. · Completed · NCT06218251
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.